Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 181 AL 195

Patents on potential drugs to treat Alzheimer's disease: special emphasis on small peptides

Sundaram P, Nambiar AK, Sundaram RK.

Recent Pat CNS Drug Discov. 2014;9(2):71-5. doi: 10.2174/1574889809666140919123006.

Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status

Vallés AS, Borroni MV, Barrantes FJ.

CNS Drugs. 2014 Nov;28(11):975-87. doi: 10.1007/s40263-014-0201-3.

The role of tau oligomers in the onset of Alzheimer's disease neuropathology

Cárdenas-Aguayo Mdel C, Gómez-Virgilio L, DeRosa S, Meraz-Ríos MA.

ACS Chem Neurosci. 2014 Dec 17;5(12):1178-91. doi: 10.1021/cn500148z. Epub 2014 Oct 15.

Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer's disease?

Rdzak GM, Abdelghany O.

Pharmacotherapy. 2014 Dec;34(12):1317-23. doi: 10.1002/phar.1494. Epub 2014 Oct 3.

Advances in recent patent and clinical trial drug development for Alzheimer's disease

Liu H, Wang L, Su W, Xie XQ.

Pharm Pat Anal. 2014 Jul;3(4):429-47. doi: 10.4155/ppa.14.22.

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease

Lawlor B, Kennelly S, O'Dwyer S, Cregg F, Walsh C, Coen R, Kenny RA, Howard R, Murphy C, Adams J, Daly L, Segurado R, Gaynor S, Crawford F, Mullan M, Lucca U, Banzi R, Pasquier F, Breuilh L, Riepe M, Kalman J, Wallin A, Borjesson A, Molloy W, Tsolaki M, Olde Rikkert M.

BMJ Open. 2014 Oct 9;4(10):e006364. doi: 10.1136/bmjopen-2014-006364.

Genetics of Alzheimer's disease

Chouraki V, Seshadri S.

Adv Genet. 2014;87:245-94. doi: 10.1016/B978-0-12-800149-3.00005-6.

Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus

Mushtaq G, Greig NH, Khan JA, Kamal MA.

CNS Neurol Disord Drug Targets. 2014;13(8):1432-9. doi: 10.2174/1871527313666141023141545.

Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer's disease

Ahmad MZ, Ahmad J, Amin S, Rahman M, Anwar M, Mallick N, Ahmad FJ, Rahman Z, Kamal MA, Akhter S.

CNS Neurol Disord Drug Targets. 2014;13(8):1315-24. doi: 10.2174/1871527313666141023100618.

FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease

Paroni G, Seripa D, Fontana A, D'Onofrio G, Gravina C, Urbano M, Cascavilla L, Pellegrini F, Greco A, Pilotto A.

Clin Interv Aging. 2014 Oct 21;9:1783-91. doi: 10.2147/CIA.S64758. eCollection 2014.

Structure and mechanism of action of tau aggregation inhibitors

Cisek K, Cooper GL, Huseby CJ, Kuret J.

Curr Alzheimer Res. 2014;11(10):918-27. doi: 10.2174/1567205011666141107150331.

Epigenetic nutraceutical diets in Alzheimer's disease

Davinelli S, Calabrese V, Zella D, Scapagnini G.

J Nutr Health Aging. 2014 Nov;18(9):800-5. doi: 10.1007/s12603-014-0552-y.

The Intracellular Domain of Amyloid Precursor Protein is a Potential Therapeutic Target in Alzheimer's Disease

Nagase H, Nakayama K.

Curr Drug Discov Technol. 2014;11(4):243-58. doi: 10.2174/1570163811666141121101358.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias